Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belinostat - Onxeo

Drug Profile

Belinostat - Onxeo

Alternative Names: Beleodaq; CLN-9; PDX 101; PX-105684; PXD 101

Latest Information Update: 20 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TopoTarget
  • Developer Acrotech Biopharma; CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Onxeo SA; Servier; TopoTarget
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase II B-cell lymphoma; Glioblastoma
  • Phase I/II Non-small cell lung cancer
  • Preclinical Liver cancer; Solid tumours
  • No development reported Acute myeloid leukaemia; Bladder cancer; Carcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Fallopian tube cancer; Lymphoma; Mesothelioma; Myelodysplastic syndromes; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Thymoma
  • Discontinued Multiple myeloma

Most Recent Events

  • 06 Mar 2019 Spectrum Pharmaceuticals completes sale of belinostat to Acrotech Biopharma
  • 18 Dec 2018 National Cancer Institute plans a phase I trial for Haematological malignancies (in patients with relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome) (Combination therapy, second-line therapy or greater)(IV) in May 2019 (NCT03772925)
  • 29 Nov 2018 Belinostat is still in phase I development in Peripheral-T-cell-lymphoma (Combination therapy, First-line therapy) in USA (Spectrum Pharmaceuticals pipeline - November 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top